How to Read a ClinicalTrials.gov Listing Without a Medical Degree

Patients and caregivers come to ClinicalTrials.gov looking for a study that might help them, and many find the listings hard to follow. The listings are dense, clinical, and written in a language that assumes you already know what "non-randomized parallel assignment" and "open-label masking" mean. A CISCRP qualitative study of 30 ClinicalTrials.gov listings described the format as dense, text-heavy, and difficult to use, with an outdated design.

The reading level required to parse these pages is part of the problem. A study in the Journal of the American Medical Informatics Association found that 65% of the words in ClinicalTrials.gov trial descriptions are not in a basic medical English dictionary, and those sentences average 26.1 words, while MedlinePlus health articles use sentences 61% shorter (Wu et al., 2016). A separate analysis of 798 federally funded trials in eClinicalMedicine found that consent form language averaged a 12th-grade reading level, well above the 8th-grade average reading level of US adults (Mirza et al., 2024).

The information on these pages is useful, though buried under layers of jargon. What this guide does is pull it to the surface. We'll use a real trial listing as our example, the INSPIRE DUCHENNE gene therapy study (NCT06138639), and walk through every section a patient or caregiver would encounter. By the end, you'll know how to read any listing on the site.

The jargon you'll see on every listing

Before we get into the walkthrough, here's a quick decoder for the terms that show up most often. Bookmark this section and come back to it as needed.

The official title of our example trial reads: **"A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy."** That sentence packs in 6 distinct pieces of information, and each one tells you something about what participating would actually look like.

Phase 1/2

The study is still in early stages. Phase 1 tests whether a drug is safe. Phase 2 starts measuring whether it works. A combined Phase 1/2 does both at once, typically with a small patient count and close monitoring. If a trial is Phase 1 or 1/2, you're often among the first people to receive this treatment.

Multicenter

More than one hospital or clinic is running the study. INSPIRE DUCHENNE has 15 sites across the U.S., Canada, Italy, and the U.K.

Open-label

Everyone knows what they're getting. No placebo group, no sugar pill, no guessing. For a parent considering a gene therapy trial, it means the child will not get a placebo.

Single intravenous dose

The treatment is given once, through an IV. Some trials require weekly injections for years. This one is a one-time infusion.

In Males

Duchenne muscular dystrophy is an X-linked condition that almost exclusively affects boys. You'll see sex-specific eligibility in many genetic disease trials.

Study design, decoded

Below the title, ClinicalTrials.gov shows a cluster of fields labeled things like "Study Type," "Allocation," "Intervention Model," and "Masking." These look like a form somebody filled out wrong. They're actually describing the study's architecture.

Study Type → Interventional

Participants will receive a treatment. The alternative, "Observational," is where researchers just watch and collect data without giving you anything new. If you're looking for access to a drug, you want Interventional.

Allocation → Non-Randomized

The research team decides which group you're placed in rather than a computer flipping a coin. In INSPIRE DUCHENNE, the groups are based on age, so your child's age determines the cohort. Randomized trials, where a computer assigns groups, are common in Phase 3 studies. Seeing Non-Randomized in a Phase 1/2 trial is normal.

Intervention Model → Parallel

Multiple groups run at the same time. In this trial, the registry lists 5 age-based cohorts as parallel groups rather than groups that run one after another. The alternative is "Sequential" (each group finishes before the next begins) or "Crossover" (you switch groups partway through).

Masking → None (Open Label)

No blinding. ClinicalTrials.gov can mark 4 roles as blinded, the participant, the care provider, the investigator and the outcomes assessor. Records marked "Single" list 1 of them, "Double" 2, "Triple" 3 and "Quadruple" all 4. Early gene therapy studies like this one are usually open-label, though some later ones use a placebo infusion. Sarepta's Phase 3 EMBARK study of Elevidys (NCT05096221) is registered on ClinicalTrials.gov as placebo-controlled with quadruple masking.

What the eligibility criteria are really filtering for

The eligibility section is where most patients get discouraged. It reads like a legal contract crossed with a genetics textbook. The purpose, though, is straightforward. The research team needs a group of participants similar enough to each other that the results can be interpreted clearly. Most criteria exist to control a variable or to protect participants' safety.

INSPIRE DUCHENNE's inclusion criteria start with age ranges for each cohort. These aren't arbitrary. Duchenne progresses differently at different ages, and the researchers need to measure the drug's effect against a predictable disease trajectory.

Cohort 1 (ages 4 to under 7)

Ambulatory. Must complete a 10-meter walk/run in under 30 seconds.

Cohort 2 (ages 7 to under 12)

Ambulatory. Same walk/run requirement.

Cohort 3 (ages 0 to under 4)

Youngest group. Can be walking or not yet walking, and no steroid regimen is required.

Cohort 4 (ages 12 to under 18)

Ambulatory. Same walk/run requirement as Cohorts 1 and 2.

Cohort 5 (ages 10 to under 18)

Non-ambulatory patients who were previously able to walk. If your child recently transitioned to a wheelchair, this cohort is aimed at children like them, though every other criterion still applies.

"Negative for AAV antibodies" is a criterion that trips up a lot of gene therapy candidates. AAV (adeno-associated virus) is the delivery vehicle that carries the therapeutic gene into muscle cells. If your child's immune system has already encountered a natural version of this virus, their body might attack the treatment before it can work. In a study of healthy adults, 38-72% had antibodies to common AAV types, depending on the type (Boutin et al., Human Gene Therapy, 2010). That study looked at adults and common AAV types, not children or SGT-003's own capsid, so the share who screen out of this trial is not published, but antibodies can rule out some otherwise eligible patients.

The steroid requirement is another filter. Cohorts 1, 2, 4, and 5 require a stable daily oral steroid regimen of at least 0.5mg/kg/day of prednisone or 0.75mg/kg/day of deflazacort for 12 weeks or more before screening. Steroids are standard of care in DMD, so many families will already meet this. The stability requirement helps researchers separate any change seen during the trial from the effect of a recent steroid dose change.

Endpoints tell you what the trial is actually measuring

This is the section most patients skip, and it's the one that would answer their biggest question. When you join a trial, the researchers are not measuring "did you feel better." They are measuring something precise, and that measure is central to how the FDA judges the results.

Primary endpoints (what the trial is built to answer)

Treatment-emergent adverse events through Day 360

They're counting every health problem that starts or worsens in the first year after treatment, whether or not the therapy caused it. For a Phase 1/2 trial, safety is the primary concern.

Microdystrophin protein levels at Day 90

Measured through muscle biopsies. This tells researchers whether the gene therapy is actually producing the protein it was designed to deliver.

Secondary endpoints (does it change daily life?)

North Star Ambulatory Assessment

A 17-item scale scored 0 to 34 measuring how well a child can stand, walk, and climb.

10-meter walk/run velocity

How fast your child can walk or run a short distance.

4-stair climb velocity

Timed stair climbing, a practical measure of leg strength.

6-minute walk test distance

Total distance covered walking for 6 minutes, a standard endurance measure.

Stride velocity (wearable device)

Continuous movement tracking outside the clinic, capturing real-world mobility.

Time to rise from the floor

How long it takes to stand up from lying down, directly tied to daily independence.

That gap between "protein shows up on a biopsy" and "my child can climb stairs faster" is the central tension in many gene therapy trials. A rise in microdystrophin shows the therapy is making the protein, which is not the same as showing it helps. The secondary endpoints show whether it changes daily life. Both are measured, and the FDA weighs both kinds of evidence when a sponsor seeks approval.

Status fields and what they mean for you right now

Near the top of every listing, you'll see a status label. ClinicalTrials.gov uses a specific vocabulary here, and the differences matter.

Recruiting

The trial is actively enrolling patients. You can contact the research team today. ClinicalTrials.gov listed INSPIRE DUCHENNE as Recruiting when this guide was updated in November 2026.

Active, Not Recruiting

The trial is running and participants are being treated or examined, but it is not recruiting new people right now. That can mean the spots are filled, or that enrollment was paused for another reason.

Enrolling by Invitation

The researchers choose participants from a group they decided on in advance and invite them. It is not open to everyone who meets the criteria.

Completed

The study has finished.

Terminated

Stopped early, sometimes for safety reasons, sometimes for business decisions.

Withdrawn

The study was pulled before anyone enrolled.

Not yet recruiting

The study is registered but has not started enrolling.

Suspended

The study has stopped enrolling for now and may start again.

The dates matter too. INSPIRE DUCHENNE started on May 6, 2024, with an estimated primary completion date of May 2027 and an estimated final completion date of May 2031. Primary completion is when they expect to have the main results. The 2031 date leaves room for long-term follow-up, which the FDA's 2020 gene therapy guidance recommends for up to 5 years after an AAV gene therapy, since regulators want to know the effects and safety hold up over time.

Finding study locations and the people running them

Scroll to the bottom of any ClinicalTrials.gov listing and you'll find the contacts and locations section. For INSPIRE DUCHENNE, 15 sites are listed across 4 countries. In the U.S., sites include Children's Hospital of Philadelphia, Nationwide Children's Hospital in Columbus, Seattle Children's Hospital, Lurie Children's in Chicago, UCLA, UC Davis, UC San Diego, Oregon Health & Science University, Washington University in St. Louis, Arkansas Children's Hospital, Children's Hospital of the King's Daughters in Norfolk, and Rare Disease Research in Atlanta. International sites include The Hospital for Sick Children in Toronto, Policlinico Gemelli in Rome, and Great Ormond Street Hospital in London.

Each site lists a contact person with a phone number and email. These are typically the research coordinators, not the principal investigators. The PI (principal investigator) is the doctor leading the study at that specific site. INSPIRE DUCHENNE's PI list includes names like Kevin Flanigan at Nationwide Children's, Perry Shieh at UCLA, Francesco Muntoni at Great Ormond Street, and Eugenio Mercuri in Rome. These are physicians you can look up independently to understand their expertise and publication history.

What ClinicalTrials.gov doesn't tell you

Every listing has gaps. ClinicalTrials.gov won't tell you how many of the 60 estimated enrollment slots have already been filled. It won't tell you the travel reimbursement policy. It won't describe the visit schedule, how many times you'll need to come back for assessments, blood draws, and MRIs over 5 years of follow-up. It won't explain whether you'll need to stay near the trial site for days after the infusion for monitoring, or whether the sponsor covers lodging.

For gene therapy trials specifically, listings often leave out the immunosuppression plan. Many AAV gene therapies are given with extra steroids before and after the infusion to manage the immune response to the viral vector. The duration and intensity of that steroid regimen varies by trial and can significantly affect how your child feels in the weeks following treatment.

These details live in the full protocol document, which is sometimes linked from the listing page but more often isn't. The fastest way to get them is to call the site coordinator listed in the contacts section and ask directly.

Applying this to any listing

We used INSPIRE DUCHENNE as the walkthrough, but the structure is much the same across the more than 600,000 studies on ClinicalTrials.gov. Most listings share the same core fields. The title always packs in the phase, design, and population. The eligibility criteria always serve the same purpose of defining a study group tight enough to produce interpretable results. The endpoints always reveal what the researchers consider success. The status usually tells you whether you can act today or whether the window has closed.

If you're looking at a trial for a different condition, Trial Friend translates these listings into plain language automatically. Search by your condition, and the trial pages will break down the same fields covered here, along with side effect data from the FDA, drug mechanism explanations, and study location maps. If a listing still confuses you after reading this guide, ask our chatbot on any Trial Friend page to walk through it with you.